Elafibranor + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Conditions
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Trial Timeline
Mar 1, 2016 → Oct 28, 2020
NCT ID
NCT02704403About Elafibranor + Placebo
Elafibranor + Placebo is a phase 3 stage product being developed by Genfit for Nonalcoholic Steatohepatitis (NASH) With Fibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02704403. Target conditions include Nonalcoholic Steatohepatitis (NASH) With Fibrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02704403 | Phase 3 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH) With Fibrosis